David E. Avigan
Expertise in
34
conditions

Dr. David E. Avigan

Internal Medicine
330 Brookline Avenue, 
Boston, MA 
Accepting New Patients
33 Years of Experience
Before you request
Expertise in
34
conditions
330 Brookline Avenue, 
Boston, MA 

Overview

David Avigan is a primary care provider, practicing in Internal Medicine in Boston, Massachusetts. He has been practicing medicine for over 33 years.

Dr. Avigan is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Bone Marrow Aspiration.

Dr. Avigan is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 120 peer reviewed articles and participating in 10 clinical trials. Dr. Avigan is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in MA

Board Certifications

American Board Of Internal Medicine

Fellowships

Memorial Sloan- Kettering Cancer Center

Hospital Affiliations

Beth Israel Deaconess Hospital - Needham
Beth Israel Deaconess Medical Center

Languages Spoken

English
Hebrew
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Boston, MA 02215

Additional Areas of Focus

Dr. Avigan has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Leukemia
Multiple Myeloma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and, Diffuse Large B Cell Lymphoma and T- Cell Non-Hodgkin Lymphoma
A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and, Diffuse Large B Cell Lymphoma and T- Cell Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: April 03, 2026
Intervention Type: Drug
Study Drugs: GO-203-2C, Decitabine
Study Phase: Phase 1/Phase 2
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug, Procedure
Study Drugs: Lenalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 3
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
Enrollment Status: Completed
Publish Date: April 03, 2023
Phase I/II Study of Lenalidomide in Combination With Anti-PD-1 Monoclonal Antibody CT-011 in Patients With Relapsed/Refractory Multiple Myeloma
Phase I/II Study of Lenalidomide in Combination With Anti-PD-1 Monoclonal Antibody CT-011 in Patients With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: January 27, 2023
Intervention Type: Other, Biological, Drug
Study Phase: Phase 1
A Phase I Study to Investigate the Safety, Tolerability and Preliminary Efficacy of TEG002 Infusion in Relapsed/Refractory Multiple Myeloma Patients
A Phase I Study to Investigate the Safety, Tolerability and Preliminary Efficacy of TEG002 Infusion in Relapsed/Refractory Multiple Myeloma Patients
Enrollment Status: Unknown
Publish Date: September 08, 2022
Intervention Type: Biological
Study Drug: TEG002
Study Phase: Phase 1
A Randomized Placebo-controlled Phase II Trial of Irradiated, Adenovirus Vector Transferred GM-CSF Secreting Autologous Leukemia Cell Vaccination (GVAX) Versus Placebo Vaccination in Patients With Advanced MDS/AML After Allogeneic Hematopoietic Stem Cell Transplantation
A Randomized Placebo-controlled Phase II Trial of Irradiated, Adenovirus Vector Transferred GM-CSF Secreting Autologous Leukemia Cell Vaccination (GVAX) Versus Placebo Vaccination in Patients With Advanced MDS/AML After Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: July 18, 2022
Intervention Type: Procedure, Biological, Drug
Study Drugs: Busulfan, Fludarabine, Tacrolimus, Methotrexate, GM-CSF-Positive GVAX Vaccine
Study Phase: Phase 2
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: June 24, 2021
Intervention Type: Biological, Other
Study Phase: Phase 1
A Phase II Study of Reduced Intensity Double Umbilical Cord Blood Transplantation Using Fludarabine, Melphalan, and Low Dose Total Body Radiation
A Phase II Study of Reduced Intensity Double Umbilical Cord Blood Transplantation Using Fludarabine, Melphalan, and Low Dose Total Body Radiation
Enrollment Status: Completed
Publish Date: January 23, 2019
Intervention Type: Biological, Radiation, Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

120 Total Publications

CD137 in cancer therapy - bench to bedside.
CD137 in cancer therapy - bench to bedside.
Journal: Immunotherapy
Published: July 10, 2026
Similar Doctors
Expertise in
24
conditions
Dr. Nezam H. Afdhal
Internal Medicine
Expertise in
24
conditions
Dr. Nezam H. Afdhal
Internal Medicine
Before you request

BIDMC - Division Of Gastroenterology/Liver Center

110 Francis Street, 
Boston, MA 
 (0.3 miles away)
617-632-1070
Languages Spoken:
English, Farsi
See accepted insurances
Accepting New Patients

Nezam Afdhal is a primary care provider, practicing in Internal Medicine in Boston, Massachusetts. Dr. Afdhal is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Hepatitis C, Hepatitis, Nonalcoholic Steatohepatitis (NASH), Liver Transplant, and Endoscopy. Dr. Afdhal is currently accepting new patients.

Expertise in
22
conditions
Dr. Gabriela S. Hobbs
Internal Medicine
Expertise in
22
conditions
Dr. Gabriela S. Hobbs
Internal Medicine

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (2.5 miles away)
617-724-1124
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gabriela Hobbs is a primary care provider, practicing in Internal Medicine in Boston, Massachusetts. She has been practicing medicine for over 18 years. Dr. Hobbs is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Myeloproliferative Neoplasms (MPN), Myelofibrosis, Polycythemia Vera, Bone Marrow Aspiration, and Colonoscopy. Dr. Hobbs is currently accepting new patients.

Expertise in
24
conditions
Dr. Adnan J. Majid
Internal Medicine
Expertise in
24
conditions
Dr. Adnan J. Majid
Internal Medicine
Before you request

Medical And Surgical Specialties

200 Boylston Street, 
Chestnut Hill, MA 
 (3.9 miles away)
617-632-8252
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Adnan Majid is a primary care provider, practicing in Internal Medicine in Chestnut Hill, Massachusetts. Dr. Majid is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Tracheobronchomalacia, Acquired Tracheomalacia, Parapneumonic Pleural Effusion, Advanced Bronchoscopy, and Endoscopy. Dr. Majid is board certified in American Board Of Internal Medicine. Dr. Majid is currently accepting new patients.

Frequently Asked Questions about Dr. David E. Avigan

How do I make an appointment with Dr. David E. Avigan?

You can book an appointment with Dr. David E. Avigan by calling their office at 617-667-9920. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David E. Avigan a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David E. Avigan is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David E. Avigan specialize in?

While Dr. David E. Avigan is a Internal Medicine, they have specific expertise in Multiple Myeloma, Acute Myeloid Leukemia (AML), and Non-Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. David E. Avigan participate in research or clinical trials?

Yes. Dr. David E. Avigan has published 120 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. David E. Avigan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David E. Avigan accept my insurance?

Dr. David E. Avigan accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-667-9920 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Avigan's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 23 Advanced Conditions
View All 35 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile